Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on Long-Term Safety of Adalimumab for Children with Ulcerative Colitis Who Completed Previous Study

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the long-term safety and tolerability of a medication called adalimumab in children with Ulcerative Colitis. Ulcerative Colitis is a chronic condition that causes inflammation and sores in the lining of the large intestine. The medication being tested, adalimumab, is a type of drug known as a monoclonal antibody, which is designed to target and block a specific protein in the body that causes inflammation.

The purpose of this study is to evaluate how safe and well-tolerated adalimumab is when given repeatedly over a long period. Participants in this study are children who have previously completed a related study, known as Protocol M11-290. During the study, participants will receive adalimumab as a solution for injection, which means the medication is administered through a needle under the skin. The study will monitor the participants' health and any side effects they may experience while taking the medication.

This study is open-label, meaning both the researchers and participants know which treatment is being administered. The study will continue to observe the participants to ensure the medication is safe and effective in maintaining a clinical response, which refers to the improvement of symptoms associated with Ulcerative Colitis. The study aims to provide valuable information about the long-term use of adalimumab in managing this condition in children.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Participation begins after successful completion of a previous study, Protocol M11-290, through Week 52.

    Eligibility is confirmed based on prior study completion.

  2. Step 2

    Medication administration

    The medication used in this study is adalimumab, administered as a solution for injection.

    The injections are given subcutaneously (under the skin).

    Available dosages include 40 mg, 80 mg, and 20 mg, provided in pre-filled syringes.

  3. Step 3

    Treatment schedule

    The study involves repeated administration of adalimumab to evaluate long-term safety and tolerability.

    The frequency and duration of administration are determined by the study protocol and medical team.

  4. Step 4

    Monitoring and evaluation

    The study aims to assess the long-term safety and maintenance of clinical response to adalimumab.

    Efficacy is measured using the Pediatric Ulcerative Colitis Activity Index (PUCAI) and other scoring systems if available.

  5. Step 5

    Safety analysis

    Safety analyses are conducted for all participants who receive at least one dose of the study drug.

    The study is designed to ensure the well-being of participants throughout the trial.

  6. Step 6

    Study duration

    The estimated end date for the study is May 14, 2025.

    The study is conducted over several years to gather comprehensive data on long-term effects.

Who can join the trial?

5 criteria

  • The patient must have a condition called Ulcerative Colitis, which is a disease that causes inflammation and sores in the colon and rectum.
  • The patient must have successfully enrolled in and completed a previous study called Protocol M11-290 through Week 52.
  • The patient must be a child or teenager, as the study is for pediatric subjects.
  • Both boys and girls can participate in the study.
  • The study includes individuals who may be considered part of a vulnerable population, meaning they might need extra care or protection.

Who cannot join the trial?

5 criteria

  • Patients who have not successfully completed the previous study, Protocol M11-290, through Week 52 cannot participate.
  • Patients with medical conditions other than Ulcerative Colitis that might interfere with the study cannot participate.
  • Patients who are not within the specified age range for the study cannot participate.
  • Patients who are not able to follow the study procedures or attend the required visits cannot participate.
  • Patients who have any other health issues that the study doctors think might make it unsafe for them to participate cannot participate.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Adalimumab is a medication used in this clinical trial. It is a human anti-TNF monoclonal antibody. The trial aims to evaluate the long-term safety and tolerability of repeated administration of this medication in children with ulcerative colitis. Adalimumab works by reducing inflammation in the body, which can help manage symptoms of ulcerative colitis. The study focuses on ensuring that the medication is safe and effective for long-term use in pediatric patients who have already completed a previous study with this treatment.

What is already known about the treatment

Adalimumab – Adalimumab is administered via subcutaneous injection and is currently being studied for its long-term safety and tolerability in pediatric patients with ulcerative colitis. It is a well-established medication in medical literature, primarily used for treating various inflammatory conditions. The main therapeutic indication for adalimumab in this study is ulcerative colitis, a chronic inflammatory bowel disease. At the molecular level, adalimumab works by blocking tumor necrosis factor (TNF), a substance in the body that causes inflammation. It is classified as a human anti-TNF monoclonal antibody, which helps reduce inflammation and improve symptoms in affected patients.

Investigated diseases

Ulcerative Colitis – Ulcerative colitis is a chronic inflammatory condition affecting the colon and rectum. It is characterized by inflammation and ulceration of the innermost lining of the large intestine. Symptoms often include abdominal pain, diarrhea, and rectal bleeding. The disease typically progresses with periods of flare-ups and remissions. Over time, the inflammation can lead to complications such as strictures or increased risk of colon cancer. The exact cause is unknown, but it is believed to involve an abnormal immune response in the gut.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2023-504711-32-00Protocol codeM10-870Estimated enrolment59 patientsSponsorAbbVie Deutschland GmbH & Co. KG

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.